Liver Resections in Metastatic Gastric Cancer

Overview

Journal HPB (Oxford)

Publisher Elsevier

Specialty Gastroenterology

Date 2010 Oct 22

PMID 20961366

Citations 26

Authors

Sid P Kerkar

Clinton D Kemp

Itzhak Avital

Affiliations

Soon will be listed here.

Abstract

Background: The 5-year survival of patients receiving standard-of-care chemotherapy for metastatic gastric cancer (MGC) to the liver is <2%. This review examines the published data on liver resections for MGC and analyses the rationale for potentially aggressive surgical management.

Methods: A search of the PubMed and Scopus databases was used to identify studies published in English from 1990 to 2009 that reported on 10 or more patients who underwent liver resections for MGC. All available clinicopathologic data were analysed. In particular, we examined longterm survival and the characteristics of individuals surviving for >5 years.

Results: Nineteen studies reported on 436 patients. Median 5-year survival was 26.5% (range: 0-60%). Overall, 13.4% (48/358) of patients were alive at 5 years and studies with extended follow-up reported that 4.0% (7/174) of patients survived for >10 years. Overall in-hospital mortality was 3.5% (12/340 patients); however, the median mortality rate across the studies was 0%. No prognostic factor was found to be consistently statistically significant across these small studies.

Conclusions: Despite the limitations of any analysis of retrospective data for highly selected groups of patients, it would appear that liver resections combined with systemic therapy for MGC can result in prolonged survival.

Citing Articles

Surgical Resection Enhances Survival in Patients With Liver Metastases From Gastric Cancer: A Population-Based, Case-Control Study.

Sun W, Li X Health Sci Rep. 2024; 7(12):e70220.

PMID: 39669188 PMC: 11635178. DOI: 10.1002/hsr2.70220.

Analysis of risk factors for liver metastasis in patients with gastric cancer and construction of prediction model: A multicenter study.

Yu H, Jiang H, Lu X, Bai C, Song P, Sun F Discov Oncol. 2024; 15(1):363.

PMID: 39167254 PMC: 11339001. DOI: 10.1007/s12672-024-01246-z.

Benefit of a multimodal approach combining chemotherapy and surgery in oligometastatic gastric cancer: experience from a tertiary referral center.

Maratta M, Vitale A, Basso M, Vivolo R, Di Monte E, Biondi A Front Oncol. 2024; 14:1343596.

PMID: 38912067 PMC: 11190071. DOI: 10.3389/fonc.2024.1343596.

Establishment and evaluation of a prognostic model for patients with unresectable gastric cancer liver metastases.

Chang Z, Gao W, Zhang Y, Zhao W, Wu D, Chen L World J Clin Cases. 2024; 12(13):2182-2193.

PMID: 38808342 PMC: 11129128. DOI: 10.12998/wjcc.v12.i13.2182.

The Japanese nationwide cohort data of proton beam therapy for liver oligometastasis in esophagogastric cancer patients.

Yamaguchi H, Fukumitsu N, Numajiri H, Ogino H, Katoh N, Okimoto T J Radiat Res. 2023; 64(6):926-932.

PMID: 37697668 PMC: 10665303. DOI: 10.1093/jrr/rrad066.

References

Cao W, Yang W, Lou G, Jiang J, Geng M, Xi W . Phase II trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) as first-line treatment for advanced gastric cancer. Anticancer Drugs. 2009; 20(4):287-93. DOI: 10.1097/CAD.0b013e3283273509. View

Murad A, Santiago F, Petroianu A, Rocha P, Rodrigues M, Rausch M . Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 1993; 72(1):37-41. DOI: 10.1002/1097-0142(19930701)72:1<37::aid-cncr2820720109>3.0.co;2-p. View

Roh H, Suh K, Lee H, Yang H, Choe K, Lee K . Outcome of hepatic resection for metastatic gastric cancer. Am Surg. 2005; 71(2):95-9. View

Elias D, Cavalcanti de Albuquerque A, Eggenspieler P, Plaud B, Ducreux M, Spielmann M . Resection of liver metastases from a noncolorectal primary: indications and results based on 147 monocentric patients. J Am Coll Surg. 1998; 187(5):487-93. DOI: 10.1016/s1072-7515(98)00225-7. View

Sakamoto Y, Ohyama S, Yamamoto J, Yamada K, Seki M, Ohta K . Surgical resection of liver metastases of gastric cancer: an analysis of a 17-year experience with 22 patients. Surgery. 2003; 133(5):507-11. DOI: 10.1067/msy.2003.147. View

Sakamoto Y, Sano T, Shimada K, Esaki M, Saka M, Fukagawa T . Favorable indications for hepatectomy in patients with liver metastasis from gastric cancer. J Surg Oncol. 2007; 95(7):534-9. DOI: 10.1002/jso.20739. View

Saiura A, Umekita N, Inoue S, Maeshiro T, Miyamoto S, Matsui Y . Clinicopathological features and outcome of hepatic resection for liver metastasis from gastric cancer. Hepatogastroenterology. 2002; 49(46):1062-5. View

Zacherl J, Zacherl M, Scheuba C, Steininger R, Wenzl E, Muhlbacher F . Analysis of hepatic resection of metastasis originating from gastric adenocarcinoma. J Gastrointest Surg. 2002; 6(5):682-9. DOI: 10.1016/s1091-255x(01)00075-0. View

Bines S, England G, Deziel D, Witt T, Doolas A, ROSEMAN D . Synchronous, metachronous, and multiple hepatic resections of liver tumors originating from primary gastric tumors. Surgery. 1993; 114(4):799-805; discussion 804-5. View

10.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M . Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4):225-49. DOI: 10.3322/caac.20006. View

11.

Morise Z, Sugioka A, Hoshimoto S, Kato T, Ikeda M, Uyama I . The role of hepatectomy for patients with liver metastases of gastric cancer. Hepatogastroenterology. 2008; 55(85):1238-41. View

12.

Okano K, Maeba T, Ishimura K, Karasawa Y, Goda F, Wakabayashi H . Hepatic resection for metastatic tumors from gastric cancer. Ann Surg. 2001; 235(1):86-91. PMC: 1422399. DOI: 10.1097/00000658-200201000-00011. View

13.

Sarmiento J, Heywood G, Rubin J, Ilstrup D, Nagorney D, Que F . Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003; 197(1):29-37. DOI: 10.1016/S1072-7515(03)00230-8. View

14.

Fujii K, Fujioka S, Kato K, Machiki Y, KUTSUNA Y, Ishikawa A . Resection of liver metastasis from gastric adenocarcinoma. Hepatogastroenterology. 2001; 48(38):368-71. View

15.

Cheon S, Rha S, Jeung H, Im C, Kim S, Kim H . Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases. Ann Oncol. 2008; 19(6):1146-53. DOI: 10.1093/annonc/mdn026. View

16.

Ajani J . Evolving chemotherapy for advanced gastric cancer. Oncologist. 2005; 10 Suppl 3:49-58. DOI: 10.1634/theoncologist.10-90003-49. View

17.

Lee J, Kang W, Kwon J, Oh S, Lee H, Kim H . Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma. Ann Oncol. 2006; 18(1):88-92. DOI: 10.1093/annonc/mdl317. View

18.

Ambiru S, Miyazaki M, Ito H, Nakagawa K, Shimizu H, Yoshidome H . Benefits and limits of hepatic resection for gastric metastases. Am J Surg. 2001; 181(3):279-83. DOI: 10.1016/s0002-9610(01)00567-0. View

19.

Kerkar S, Kemp C, Duffy A, Kammula U, Schrump D, Kwong K . The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone. Trials. 2009; 10:121. PMC: 2803175. DOI: 10.1186/1745-6215-10-121. View

20.

DAngelica M, Gonen M, Brennan M, Turnbull A, Bains M, Karpeh M . Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg. 2004; 240(5):808-16. PMC: 1356486. DOI: 10.1097/01.sla.0000143245.28656.15. View